Peter Jacko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Peter Jacko has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Arash Asadi
Wireless Communication and Sensing Lab, Delft University of Technology, Delft, Netherlands
4 shared publications - Sofia S. Villar
University of Cambridge
4 shared publications - Vincenzo Mancuso
University of Palermo, Palermo, Italy
4 shared publications - Ahmed Kheiri
The University of Manchester, Manchester, United Kingdom
3 shared publications - Christopher Kirkbride
Department of Management Science Lancaster University Management School United Kingdom
3 shared publications - Konstantin Avrachenkov
Inria, Université Côte d’Azur
3 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by SAGE Publications in Clinical Trials
- Vol. 23 (5) , 472-481
Adaptive versus fixed designs in confirmatory clinical trials: centering the choice on ethics
Background: Because confirmatory clinical trials are costly, large-scale endeavors, the choice of their design carries significant weight. While the current methodological landscape offers tools to address residual pre-trial uncertainty through prespecified adaptations to design elements, design choices remain frequently constrained by prevailing orthodoxies. Methods: We examine how unacknowledged design uncertainties (e.g., sample size calculations based on incorrect effect size or variance estimates) impact the statistical, ethical, and resource-stewardship goals of confirmatory trials. We contrast how fixed and adaptive design strategies handle these uncertainties, detailing the operational safeguards, firewalls, and trade-offs (e.g., complexity, operational bias) required to preserve trial integrity. Results: Strict adherence to default templates prevents stakeholders from matching the design strategy to the specific complexities of the research question. We observe that the gold standard status of fixed designs often obscures their limitations in handling design uncertainties. A rigid adherence to these conventions can ethically hinder a trial’s ability to deliver conclusive results. Conversely, while adaptive designs can offer tools to efficiently reduce uncertainty, we acknowledge that adaptive elements are not without cost; their implementation requires rigorous safeguards to manage specific risks to trial integrity and potential operational biases. Conclusion: To better align clinical research with its ethical and scientific mandates, we issue two calls to action. First, trial designers, including statisticians, must clearly articulate how target and design uncertainties impact ethical obligations, promoting an open-minded evaluation of both fixed and adaptive methods. Second, stakeholders must foreground ethical considerations during design selection, requiring explicit justification for the use—or non-use—of adaptive elements. The ethical path forward is not to default to the old or blindly adopt the new, but to explicitly justify the chosen design based on its responsiveness to the specific uncertainties of the trial. We posit that trial design must transition from a habit-based process to one where pre-trial uncertainties are openly discussed and addressed.
- 4 August 2026
- Published by SAGE Publications in Clinical Trials
- Vol. 23 (5) , 472-481
Open AccessAdaptive versus fixed designs in confirmatory clinical trials: centering the choice on ethics
Background: Because confirmatory clinical trials are costly, large-scale endeavors, the choice of their design carries significant weight. While the current methodological landscape offers tools to address residual pre-trial uncertainty through prespecified adaptations to design elements, design choices remain frequently constrained by prevailing orthodoxies. Methods: We examine how unacknowledged design uncertainties (e.g., sample size calculations based on incorrect effect size or variance estimates) impact the statistical, ethical, and resource-stewardship goals of confirmatory trials. We contrast how fixed and adaptive design strategies handle these uncertainties, detailing the operational safeguards, firewalls, and trade-offs (e.g., complexity, operational bias) required to preserve trial integrity. Results: Strict adherence to default templates prevents stakeholders from matching the design strategy to the specific complexities of the research question. We observe that the gold standard status of fixed designs often obscures their limitations in handling design uncertainties. A rigid adherence to these conventions can ethically hinder a trial’s ability to deliver conclusive results. Conversely, while adaptive designs can offer tools to efficiently reduce uncertainty, we acknowledge that adaptive elements are not without cost; their implementation requires rigorous safeguards to manage specific risks to trial integrity and potential operational biases. Conclusion: To better align clinical research with its ethical and scientific mandates, we issue two calls to action. First, trial designers, including statisticians, must clearly articulate how target and design uncertainties impact ethical obligations, promoting an open-minded evaluation of both fixed and adaptive methods. Second, stakeholders must foreground ethical considerations during design selection, requiring explicit justification for the use—or non-use—of adaptive elements. The ethical path forward is not to default to the old or blindly adopt the new, but to explicitly justify the chosen design based on its responsiveness to the specific uncertainties of the trial. We posit that trial design must transition from a habit-based process to one where pre-trial uncertainties are openly discussed and addressed.
- Open Access
- 25 March 2026
- Published by SAGE Publications in Statistical Methods in Medical Research
- Vol. 35 (11) , 2287-2319
Randomization and allocation procedures for master protocol trials of single-arm studies
In this paper we propose and examine randomization and allocation procedures in master protocol trials where each subtrial is performed as a single-arm study, which is motivated mainly by rare diseases. The subtrial analysis is done by comparing the single-arm observations data to historical data or expert judgment and following prespecified decision rules, without using data from any other study in the master protocol trial. The objective of this paper is to examine relevant options for participant allocation procedures in a variety of patterns in which the subtrials enter the master protocol trial, such as umbrella, platform and perpetual patterns. Our simulation study shows that our proposed allocation procedures using the predictive probability of current study success may bring substantial efficiency gains in the master protocol trial, making a clever allocation of the in-trial participants to achieve study success declarations sooner, benefiting the out-of-trial population.
- 25 March 2026
- Published by SAGE Publications in Statistical Methods in Medical Research
- Vol. 35 (11) , 2287-2319
Open AccessRandomization and allocation procedures for master protocol trials of single-arm studies
In this paper we propose and examine randomization and allocation procedures in master protocol trials where each subtrial is performed as a single-arm study, which is motivated mainly by rare diseases. The subtrial analysis is done by comparing the single-arm observations data to historical data or expert judgment and following prespecified decision rules, without using data from any other study in the master protocol trial. The objective of this paper is to examine relevant options for participant allocation procedures in a variety of patterns in which the subtrials enter the master protocol trial, such as umbrella, platform and perpetual patterns. Our simulation study shows that our proposed allocation procedures using the predictive probability of current study success may bring substantial efficiency gains in the master protocol trial, making a clever allocation of the in-trial participants to achieve study success declarations sooner, benefiting the out-of-trial population.
- Open Access
- 8 December 2025
- Published by Elsevier in European Journal of Operational Research
- Vol. 332 (3) , 840-856
A bi-objective Markov decision process design approach to redundancy allocation with dynamic maintenance for a parallel system
- 8 December 2025
- Published by Elsevier in European Journal of Operational Research
- Vol. 332 (3) , 840-856
Open AccessA bi-objective Markov decision process design approach to redundancy allocation with dynamic maintenance for a parallel system
- Open Access
- 14 July 2025
- Published by Association for Computing Machinery (ACM)
- p. 131-134
CoSPLib - A Benchmark Library for Conference Scheduling Problems
- 14 July 2025
- Published by Association for Computing Machinery (ACM)
- p. 131-134
Open AccessCoSPLib - A Benchmark Library for Conference Scheduling Problems
- Open Access
- 17 January 2025
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 25 (1) , 1-11
Why and how should we simulate platform trials? Learnings from EU-PEARL
Platform trials are innovative clinical trials governed by a master protocol that allows for the evaluation of multiple investigational treatments that enter and leave the trial over time. Interest in platform trials has been steadily increasing over the last decade. Due to their highly adaptive nature, platform trials provide sufficient flexibility to customize important trial design aspects to the requirements of both the specific disease under investigation and the different stakeholders. The flexibility of platform trials, however, comes with complexities when designing such trials. In the past, we reviewed existing software for simulating clinical trials and found that none of them were suitable for simulating platform trials as they do not accommodate the design features and flexibility inherent to platform trials, such as staggered entry of treatments over time. We argued that simulation studies are crucial for the design of efficient platform trials. We developed and proposed an iterative, simulation-guided “vanilla and sprinkles” framework, i.e. from a basic to a more complex design, for designing platform trials. We addressed the functionality limitations of existing software as well as the unavailability of the coding therein by developing a suite of open-source software to use in simulating platform trials based on the R programming language. To give some examples, the newly developed software supports simulating staggered entry of treatments throughout the trial, choosing different options for control data sharing, specifying different platform stopping rules and platform-level operating characteristics. The software we developed is available through open-source licensing to enable users to access and modify the code. The separate use of two of these software packages to implement the same platform design by independent teams obtained the same results. We provide a framework, as well as open-source software for the design and simulation of platform trials. The software tools provide the flexibility necessary to capture the complexity of platform trials.
- 17 January 2025
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 25 (1) , 1-11
Open AccessWhy and how should we simulate platform trials? Learnings from EU-PEARL
Platform trials are innovative clinical trials governed by a master protocol that allows for the evaluation of multiple investigational treatments that enter and leave the trial over time. Interest in platform trials has been steadily increasing over the last decade. Due to their highly adaptive nature, platform trials provide sufficient flexibility to customize important trial design aspects to the requirements of both the specific disease under investigation and the different stakeholders. The flexibility of platform trials, however, comes with complexities when designing such trials. In the past, we reviewed existing software for simulating clinical trials and found that none of them were suitable for simulating platform trials as they do not accommodate the design features and flexibility inherent to platform trials, such as staggered entry of treatments over time. We argued that simulation studies are crucial for the design of efficient platform trials. We developed and proposed an iterative, simulation-guided “vanilla and sprinkles” framework, i.e. from a basic to a more complex design, for designing platform trials. We addressed the functionality limitations of existing software as well as the unavailability of the coding therein by developing a suite of open-source software to use in simulating platform trials based on the R programming language. To give some examples, the newly developed software supports simulating staggered entry of treatments throughout the trial, choosing different options for control data sharing, specifying different platform stopping rules and platform-level operating characteristics. The software we developed is available through open-source licensing to enable users to access and modify the code. The separate use of two of these software packages to implement the same platform design by independent teams obtained the same results. We provide a framework, as well as open-source software for the design and simulation of platform trials. The software tools provide the flexibility necessary to capture the complexity of platform trials.
- Open Access
- 14 July 2024
- Published by Association for Computing Machinery (ACM)
- p. 1732-1737
Efficient Scheduling of GECCO Conferences using Hyper-heuristic Algorithms
We propose the development of a conference scheduler tailored specifically for the Genetic and Evolutionary Computation Conference (GECCO). Our proposed flexible approach allows GECCO organisers to optimise conference schedules according to their specific needs and available resources. Using hyper-heuristic methods, our scheduler generates optimised solutions for in-person and hybrid GECCO conferences. We validate our method using data from GECCO2019 and demonstrate its effectiveness by successfully creating schedules for GECCO conferences from 2020 onwards.
- 14 July 2024
- Published by Association for Computing Machinery (ACM)
- p. 1732-1737
Open AccessEfficient Scheduling of GECCO Conferences using Hyper-heuristic Algorithms
We propose the development of a conference scheduler tailored specifically for the Genetic and Evolutionary Computation Conference (GECCO). Our proposed flexible approach allows GECCO organisers to optimise conference schedules according to their specific needs and available resources. Using hyper-heuristic methods, our scheduler generates optimised solutions for in-person and hybrid GECCO conferences. We validate our method using data from GECCO2019 and demonstrate its effectiveness by successfully creating schedules for GECCO conferences from 2020 onwards.
- Open Access
- 6 April 2024
- Published by Elsevier in European Journal of Operational Research
- Vol. 317 (2) , 487-499
A generic approach to conference scheduling with integer programming
- 6 April 2024
- Published by Elsevier in European Journal of Operational Research
- Vol. 317 (2) , 487-499
Open AccessA generic approach to conference scheduling with integer programming
- Open Access
- 10 November 2023
- Published by Elsevier in European Journal of Operational Research
- Vol. 315 (2) , 454-469
A simulation-based approximate dynamic programming approach to dynamic and stochastic resource-constrained multi-project scheduling problem
- 10 November 2023
- Published by Elsevier in European Journal of Operational Research
- Vol. 315 (2) , 454-469
Open AccessA simulation-based approximate dynamic programming approach to dynamic and stochastic resource-constrained multi-project scheduling problem
- Open Access
- 5 October 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-5
Medicines and Healthcare products Regulatory Agency’s “Consultation on proposals for legislative changes for clinical trials”: a response from the Trials Methodology Research Partnership Adaptive Designs Working Group, with a focus on data sharing
In the UK, the Medicines and Healthcare products Regulatory Agency consulted on proposals “to improve and strengthen the UK clinical trials legislation to help us make the UK the best place to research and develop safe and innovative medicines”. The purpose of the consultation was to help finalise the proposals and contribute to the drafting of secondary legislation. We discussed these proposals as members of the Trials Methodology Research Partnership Adaptive Designs Working Group, which is jointly funded by the Medical Research Council and the National Institute for Health and Care Research. Two topics arose frequently in the discussion: the emphasis on legislation, and the absence of questions on data sharing. It is our opinion that the proposals rely heavily on legislation to change practice. However, clinical trials are heterogeneous, and as a result some trials will struggle to comply with all of the proposed legislation. Furthermore, adaptive design clinical trials are even more heterogeneous than their non-adaptive counterparts, and face more challenges. Consequently, it is possible that increased legislation could have a greater negative impact on adaptive designs than non-adaptive designs. Overall, we are sceptical that the introduction of legislation will achieve the desired outcomes, with some exceptions. Meanwhile the topic of data sharing — making anonymised individual-level clinical trial data available to other investigators for further use — is entirely absent from the proposals and the consultation in general. However, as an aspect of the wider concept of open science and reproducible research, data sharing is an increasingly important aspect of clinical trials. The benefits of data sharing include faster innovation, improved surveillance of drug safety and effectiveness and decreasing participant exposure to unnecessary risk. There are already a number of UK-focused documents that discuss and encourage data sharing, for example, the Concordat on Open Research Data and the Medical Research Council’s Data Sharing Policy. We strongly suggest that data sharing should be the norm rather than the exception, and hope that the forthcoming proposals on clinical trials invite discussion on this important topic.
- 5 October 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-5
Open AccessMedicines and Healthcare products Regulatory Agency’s “Consultation on proposals for legislative changes for clinical trials”: a response from the Trials Methodology Research Partnership Adaptive Designs Working Group, with a focus on data sharing
In the UK, the Medicines and Healthcare products Regulatory Agency consulted on proposals “to improve and strengthen the UK clinical trials legislation to help us make the UK the best place to research and develop safe and innovative medicines”. The purpose of the consultation was to help finalise the proposals and contribute to the drafting of secondary legislation. We discussed these proposals as members of the Trials Methodology Research Partnership Adaptive Designs Working Group, which is jointly funded by the Medical Research Council and the National Institute for Health and Care Research. Two topics arose frequently in the discussion: the emphasis on legislation, and the absence of questions on data sharing. It is our opinion that the proposals rely heavily on legislation to change practice. However, clinical trials are heterogeneous, and as a result some trials will struggle to comply with all of the proposed legislation. Furthermore, adaptive design clinical trials are even more heterogeneous than their non-adaptive counterparts, and face more challenges. Consequently, it is possible that increased legislation could have a greater negative impact on adaptive designs than non-adaptive designs. Overall, we are sceptical that the introduction of legislation will achieve the desired outcomes, with some exceptions. Meanwhile the topic of data sharing — making anonymised individual-level clinical trial data available to other investigators for further use — is entirely absent from the proposals and the consultation in general. However, as an aspect of the wider concept of open science and reproducible research, data sharing is an increasingly important aspect of clinical trials. The benefits of data sharing include faster innovation, improved surveillance of drug safety and effectiveness and decreasing participant exposure to unnecessary risk. There are already a number of UK-focused documents that discuss and encourage data sharing, for example, the Concordat on Open Research Data and the Medical Research Council’s Data Sharing Policy. We strongly suggest that data sharing should be the norm rather than the exception, and hope that the forthcoming proposals on clinical trials invite discussion on this important topic.